Can Adipose Tissue Browning Become a New Frontier in Cardiometabolic Prevention?
Atherosclerosis posted on LinkedIn:
”Can adipose tissue browning become a new frontier in cardiometabolic prevention?
Emerging research is uncovering how browning of white adipose tissue (AT) – the conversion to a more metabolically active, thermogenic phenotype – could improve both metabolic and cardiovascular health.
- Pro-inflammatory pathways (NLRP3, TLR4, NF-κB) inhibit browning
- Anti-inflammatory signals (IL-4, IL-13, M2 macrophages) promote it, enhancing insulin sensitivity and glucose tolerance
- Mitochondrial effectors – UCP-1 and PGC1-α – are key drivers of thermogenesis
- Experimental interventions (ASK-1 knockout, nitrate, melatonin) improved endothelial function, atherosclerosis, and liver steatosis
While evidence is still largely preclinical, these findings suggest that targeting adipose tissue inflammation and mitochondrial function could open new therapeutic avenues for atherosclerotic cardiovascular disease.
Could “browning” therapies become part of the next generation of cardiometabolic treatments?”
Read the full article here.
Title: Molecular mechanisms linking adipose tissue browning to reduced cardiovascular risk
Authors: Ana Checa-Rosa, Luis D’Marco

Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis